Nymox Pharmaceutical Corp (NASDAQ:NYMX)

CAPS Rating: 1 out of 5

A biopharmaceutical company with three proprietary products on the market and a R&D of drug & diagnostic products in development for the treatment of enlarged prostate, Alzheimer's disease contamination of food and drink products and bacterial infections.

Recs

1
Player Avatar zzlangerhans (99.78) Submitted: 11/10/2012 2:42:12 AM : Underperform Start Price: $8.14 NYMX Score: +20.61

When Nymox stock trailed down from steady state at 8 to below 6 this summer, I figured the smart money was leaving ahead of negative results from the phase III trials of NX-1207 for BPH. Now I'm surprised to see the share price rocketing back up close to the year high without any visible positive catalyst. This definitely doesn't have the characteristics of a run-up, so is it insider trading ahead of a positive data announcement? I can't say that's impossible, but I'm going to call it stirrapulation and place my bet on negative data from this murky trial from a very murky biopharma. The ask on Feb 2013 7.5 puts is 1.45.

Featured Broker Partners


Advertisement